
## Giuseppe Nappi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10194666/publications.pdf Version: 2024-02-01



CHISEDDE NADDI

#	Article	IF	CITATIONS
1	Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort. European Journal of Neurology, 2020, 27, 536-541.	3.3	47
2	Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: A six-month follow-up of the COMOESTAS Project. Cephalalgia, 2019, 39, 135-147.	3.9	25
3	Economic benefits of treating medication-overuse headache – results from the multicenter COMOESTAS project. Cephalalgia, 2019, 39, 274-285.	3.9	29
4	Clinical Subtypes of Medication Overuse Headache – Findings From a Large Cohort. Headache, 2019, 59, 1481-1491.	3.9	15
5	Prevalence and pathophysiology of post-prandial migraine in patients with functional dyspepsia. Cephalalgia, 2019, 39, 1560-1568.	3.9	14
6	Factors associated to chronic migraine with medication overuse: A cross-sectional study. Cephalalgia, 2018, 38, 2045-2057.	3.9	27
7	When cervical pain is actually migraine: An observational study in 207 patients. Cephalalgia, 2018, 38, 383-388.	3.9	28
8	Changes in anxiety and depression symptoms associated to the outcome of MOH: A post-hoc analysis of the Comoestas Project. Cephalalgia, 2018, 38, 646-654.	3.9	18
9	Botulinum toxin for chronic migraine: Clinical trials and technical aspects. Toxicon, 2018, 147, 111-115.	1.6	9
10	Prolonged migraine aura: new insights from a prospective diary-aided study. Journal of Headache and Pain, 2018, 19, 77.	6.0	20
11	New CACNA1A deletions are associated to migraine phenotypes. Journal of Headache and Pain, 2018, 19, 75.	6.0	25
12	Alexithymia in chronic and episodic migraine: a comparative study. Journal of Mental Health, 2017, 26, 192-196.	1.9	26
13	Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms. Cephalalgia, 2017, 37, 1272-1284.	3.9	39
14	Clinical features of migraine aura: Results from a prospective diary-aided study. Cephalalgia, 2017, 37, 979-989.	3.9	105
15	The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: A controlled multicentre study. Cephalalgia, 2017, 37, 1115-1125.	3.9	48
16	Modulation of nociceptive threshold by combined hormonal contraceptives in women with oestrogen-withdrawal migraine attacks: a pilot study. Journal of Headache and Pain, 2016, 17, 70.	6.0	19
17	Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study. Journal of Headache and Pain, 2016, 17, 20.	6.0	34
18	Psychological factors associated with failure of detoxification treatment in chronic headache associated with medication overuse. Cephalalgia, 2016, 36, 1356-1365.	3.9	28

#	Article	IF	CITATIONS
19	Variability of the characteristics of a migraine attack within patients. Cephalalgia, 2016, 36, 825-830.	3.9	41
20	Migraine aura symptoms: Duration, succession and temporal relationship to headache. Cephalalgia, 2016, 36, 413-421.	3.9	48
21	Andrographis Paniculata shows anti-nociceptive effects in an animal model of sensory hypersensitivity associated with migraine. Functional Neurology, 2016, 31, 53-60.	1.3	9
22	O010. Migraine aura symptoms last for more than one hour in more than one quarter of patients: results from a prospective diary-aided study. Journal of Headache and Pain, 2015, 16, A65.	6.0	1
23	Cost of Chronic and Episodic Migraine: a pilot study from a tertiary headache centre in northern Italy. Journal of Headache and Pain, 2015, 16, 532.	6.0	32
24	Association of <scp><i>RAMP</i></scp> <i>1</i> â€ <scp>rs</scp> 7590387 With the Risk of Migraine Transformation Into Medication Overuse Headache. Headache, 2015, 55, 658-668.	3.9	18
25	Rehabilitation from symptomatic drugs overuse: yes, no, may be. Journal of Headache and Pain, 2015, 16, A34.	6.0	0
26	O011. Patients with "prolonged aura―do not show clinical or demographic differences from the patients with "typical aura― Journal of Headache and Pain, 2015, 16, A67.	6.0	2
27	O012. Intra-variability of the characteristics of migraine attacks. Journal of Headache and Pain, 2015, 16, A70.	6.0	1
28	Clinical and Demographical Characteristics of Patients with Medication Overuse Headache in Argentina and Chile: Analysis of the Latin American Section of COMOESTAS Project. Journal of Headache and Pain, 2015, 16, 83.	6.0	30
29	Impact of headache disorders in Italy and the public-health and policy implications: a population-based study within the Eurolight Project. Journal of Headache and Pain, 2015, 16, 100.	6.0	48
30	The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias. Current Neuropharmacology, 2015, 13, 304-323.	2.9	38
31	Evaluation of ADMA-DDAH-NOS axis in specific brain areas following nitroglycerin administration: study in an animal model of migraine. Journal of Headache and Pain, 2015, 16, 560.	6.0	31
32	Triptan use in Italy: Insights from administrative databases. Cephalalgia, 2015, 35, 619-626.	3.9	19
33	Effects of peripheral FAAH blockade on NTG-induced hyperalgesia—evaluation of URB937 in an animal model of migraine. Cephalalgia, 2015, 35, 1065-1076.	3.9	50
34	Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache. European Journal of Clinical Pharmacology, 2014, 70, 1195-1202.	1.9	18
35	Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia. European Journal of Pharmacology, 2014, 744, 91-97.	3.5	19
36	Pharmacogenomics of episodic migraine: time has come for a step forward. Pharmacogenomics, 2014, 15, 541-549.	1.3	11

47

#	Article	IF	CITATIONS
37	Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia, 2014, 34, 426-433.	3.9	106
38	Diagnostic and therapeutic errors in cluster headache: a hospital-based study. Journal of Headache and Pain, 2014, 15, 56.	6.0	49
39	Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. Journal of Headache and Pain, 2014, 15, 14.	6.0	30
40	Lack of association between GRIA1 polymorphisms and haplotypes with migraine without aura or response to triptans. Neurological Sciences, 2014, 35, 421-427.	1.9	10
41	PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology. Brain, 2014, 137, 1361-1373.	7.6	54
42	Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. Cephalalgia, 2014, 34, 594-604.	3.9	64
43	Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: A placebo controlled study. Parkinsonism and Related Disorders, 2014, 20, 1140-1144.	2.2	51
44	Functional polymorphisms in <scp>COMT</scp> and <scp>SLC</scp> 6A4 genes influence the prognosis of patients with medication overuse headache after withdrawal therapy. European Journal of Neurology, 2014, 21, 989-995.	3.3	24
45	A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia, 2014, 34, 645-655.	3.9	108
46	Chronobiological correlates of headache: three decades on. Functional Neurology, 2014, 29, 213-4.	1.3	1
47	The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia, 2013, 33, 629-808.	3.9	6,757
48	Effect of Sex and Estrogens on Neuronal Activation in an Animal Model of Migraine. Headache, 2013, 53, 288-296.	3.9	39
49	SPA therapy of upper respiratory tract inflammations. European Archives of Oto-Rhino-Laryngology, 2013, 270, 565-570.	1.6	18
50	Modulation of the human nociceptive flexion reflex by pleasant and unpleasant odors. Pain, 2013, 154, 2054-2059.	4.2	36
51	An Opposite-Direction Modulation of the COMT Val158Met Polymorphism on the Clinical Response to Intrathecal Morphine and Triptans. Journal of Pain, 2013, 14, 1097-1106.	1.4	45
52	Factors associated with a negative outcome of medication-overuse headache: A 3-year follow-up (the) Tj ETQq(	) 0 0 <sub>3</sub> rgBT /	Overlock 10 <sup>-</sup>
53	Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial. Journal of Headache and Pain, 2013, 14, 10.	6.0	68

#	Article	IF	CITATIONS
55	The Antioxidant Activity of Sulphurous Thermal Water Protects against Oxidative DNA Damage: A Comet Assay Investigation. Drug Research, 2013, 63, 198-202.	1.7	19
56	Triptan nonresponders: Do they exist and who are they?. Cephalalgia, 2013, 33, 891-896.	3.9	58
57	Illicit drug use in cluster headache patients and in the general population: A comparative cross-sectional survey. Cephalalgia, 2012, 32, 1031-1040.	3.9	35
58	Free radical–scavenging activity of sulfurous water investigated by electron paramagnetic resonance (EPR) spectroscopy. Experimental Lung Research, 2012, 38, 67-74.	1.2	12
59	Neuroendocrine aspects of migraine in women. Gynecological Endocrinology, 2012, 28, 37-41.	1.7	21
60	An electronic diary on a palm device for headache monitoring: a preliminary experience. Journal of Headache and Pain, 2012, 13, 537-541.	6.0	25
61	Modulation of RAGE Isoforms Expression in the Brain and Plasma of Rats Exposed to Transient Focal Cerebral Ischemia. Neurochemical Research, 2012, 37, 1508-1516.	3.3	17
62	Italian guidelines for primary headaches: 2012 revised version. Journal of Headache and Pain, 2012, 13, 31-70.	6.0	129
63	Association of haplotype combination of serotonin transporter gene polymorphisms with monthly headache days in MOH patients. European Journal of Neurology, 2012, 19, 69-75.	3.3	11
64	Acute Reduction of Anandamideâ€Hydrolase (FAAH) Activity is Coupled With a Reduction of Nociceptive Pathways Facilitation in Medicationâ€Overuse Headache Subjects After Withdrawal Treatment. Headache, 2012, 52, 1350-1361.	3.9	49
65	Pisa syndrome in Parkinson's disease: Clinical, electromyographic, and radiological characterization. Movement Disorders, 2012, 27, 227-235.	3.9	75
66	The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review. Aging Clinical and Experimental Research, 2012, 24, 580-7.	2.9	59
67	A basic diagnostic headache diary (BDHD) is well accepted and useful in the diagnosis of headache. A multicentre European and Latin American study. Cephalalgia, 2011, 31, 1549-1560.	3.9	56
68	Childhood and adolescent migraine: A neuropsychiatric disorder?. Medical Hypotheses, 2011, 76, 778-781.	1.5	36
69	Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease. Neurobiology of Aging, 2011, 32, 2142-2151.	3.1	41
70	Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular events: evidence from a large, multicenter, cross-sectional survey in Italy (MIRACLES study). Journal of Hypertension, 2011, 29, 309-318.	0.5	29
71	Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. European Journal of Neurology, 2011, 18, 396-401.	3.3	70
72	Differences in the Personality Profile of Medication-Overuse Headache Sufferers and Drug Addict Patients: A Comparative Study Using MMPI-2. Headache, 2011, 51, 1212-1227.	3.9	27

#	Article	IF	CITATIONS
73	IkappaB-alpha expression following transient focal cerebral ischemia is modulated by nitric oxide. Brain Research, 2011, 1372, 145-151.	2.2	24
74	How parkinsonism influences life: the patients' point of view. Neurological Sciences, 2011, 32, 125-131.	1.9	11
75	Effects of anandamide in migraine: data from an animal model. Journal of Headache and Pain, 2011, 12, 177-183.	6.0	38
76	Migraine and psychiatric comorbidity: a review of clinical findings. Journal of Headache and Pain, 2011, 12, 115-125.	6.0	301
77	What do the patients with medication overuse headache expect from treatment and what are the preferred sources of information?. Journal of Headache and Pain, 2011, 12, 91-96.	6.0	28
78	Focus on the management of thunderclap headache: from nosography to treatment. Journal of Headache and Pain, 2011, 12, 251-258.	6.0	15
79	Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. Journal of Headache and Pain, 2011, 12, 427-433.	6.0	100
80	Oral nitric-oxide donor glyceryl-trinitrate induces sensitization in spinal cord pain processing in migraineurs: A double-blind, placebo-controlled, cross-over study. European Journal of Pain, 2011, 15, 482-490.	2.8	34
81	Temporal profile of vascular changes induced by systemic nitroglycerin in the meningeal and cortical districts. Cephalalgia, 2011, 31, 190-198.	3.9	36
82	Cerebrovascular diseases at the C. Mondino National Institute of Neurology: from Ottorino Rossi to the present day. Functional Neurology, 2011, 26, 87-95.	1.3	0
83	Is Hemicrania Continua a Single Entity or the Association of Two Headache Forms? Considerations From a Case Report. Headache, 2010, 50, 877-881.	3.9	7
84	Transplantation of Undifferentiated Human Mesenchymal Stem Cells Protects against 6-Hydroxydopamine Neurotoxicity in the Rat. Cell Transplantation, 2010, 19, 203-218.	2.5	136
85	Focus on therapy of primary stabbing headache. Journal of Headache and Pain, 2010, 11, 157-160.	6.0	14
86	Focus on therapy: hemicrania continua and new daily persistent headache. Journal of Headache and Pain, 2010, 11, 259-265.	6.0	21
87	A prospective multicentre study to evaluate the consistency of the IHS diagnostic criteria, the usefulness of brain MRI for the diagnosis, follow-up and treatment management, and the outcome after high dosage 6-methylprednisolone therapy, in subjects with Tolosa–Hunt syndrome. Journal of Headache and Pain, 2010, 11, 285-285.	6.0	4
88	Focus on therapy of hypnic headache. Journal of Headache and Pain, 2010, 11, 349-354.	6.0	20
89	Focus on therapy of the Chapter IV headaches provoked by exertional factors: primary cough headache, primary exertional headache and primary headache associated with sexual activity. Journal of Headache and Pain, 2010, 11, 525-530.	6.0	26
90	The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. European Journal of Pharmacology, 2010, 641, 82-87.	3.5	35

#	Article	IF	CITATIONS
91	Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease. Brain Research, 2010, 1311, 12-27.	2.2	129
92	Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study. Movement Disorders, 2010, 25, 896-905.	3.9	63
93	Biomarkers of oxidation, inflammation and cartilage degradation in osteoarthritis patients undergoing sulfur-based spa therapies. Clinical Biochemistry, 2010, 43, 973-978.	1.9	52
94	Sensitisation of spinal cord pain processing in medication overuse headache involves supraspinal pain control. Cephalalgia, 2010, 30, 272-284.	3.9	114
95	Alterations of the endocannabinoid system in an animal model of migraine: Evaluation in cerebral areas of rat. Cephalalgia, 2010, 30, 296-302.	3.9	52
96	Risk factors in medication-overuse headache: A 1-year follow-up study (care II protocol). Cephalalgia, 2010, 30, 329-336.	3.9	62
97	Medicationâ€Overuse Headache and Personality: A Controlled Study by Means of the MMPlâ€2. Headache, 2010, 50, 198-209.	3.9	35
98	Episodic Cluster Headache: NREM Prevalence of Nocturnal Attacks. Time to Look Beyond Macrostructural Analysis?. Headache, 2010, 50, 1050-1054.	3.9	31
99	Role of 2 Common Variants of 5HT2A Gene in Medication Overuse Headache. Headache, 2010, 50, 1587-1596.	3.9	16
100	Effects of sulphurous water on human neutrophil elastase release. Therapeutic Advances in Respiratory Disease, 2010, 4, 333-340.	2.6	23
101	Cluster headache and trigeminal autonomic cephalalgias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 387-388.	1.8	3
102	Other primary headaches – general aspects. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 451.	1.8	0
103	Secondary headaches. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 497-500.	1.8	1
104	Preface. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, ix-x.	1.8	0
105	Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease. Brain Research Bulletin, 2010, 82, 29-38.	3.0	48
106	Idebenone: a guide to its use in Alzheimer's disease, other age-related cognitive disorders and Friedreich's ataxia. Drugs and Therapy Perspectives, 2010, 26, 1-5.	0.6	1
107	Risk factors in medication overuse headache: A one-year follow-up study. , 2010, , 68-72.		1
108	Chapter 27 Prevention of Glutamate Accumulation and Upregulation of Phosphoâ€Akt may Account for Neuroprotection Afforded by Bergamot Essential Oil against Brain Injury Induced by Focal Cerebral Ischemia in Rat. International Review of Neurobiology, 2009, 85, 389-405.	2.0	27

#	Article	IF	CITATIONS
109	Deep brain stimulation and cognitive functions in Parkinson's disease: A threeâ€year controlled study. Movement Disorders, 2009, 24, 1621-1628.	3.9	113
110	From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries. Journal of Headache and Pain, 2009, 10, 71-76.	6.0	19
111	A narrative review on the management of medication overuse headache: the steep road from experience to evidence. Journal of Headache and Pain, 2009, 10, 407-417.	6.0	57
112	Antioxidative effects of sulfurous mineral water: protection against lipid and protein oxidation. European Journal of Clinical Nutrition, 2009, 63, 106-112.	2.9	45
113	Postâ€ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS Journal, 2009, 276, 13-26.	4.7	370
114	Diagnostic Delay and Suboptimal Management in a Referral Population With Hemicrania Continua. Headache, 2009, 49, 227-234.	3.9	57
115	Implementation and evaluation of existing guidelines on the use of neurophysiological tests in non-acute migraine patients: a questionnaire survey of neurologists and primary care physicians. European Journal of Neurology, 2009, 16, 937-942.	3.3	5
116	BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease. European Journal of Neurology, 2009, 16, 1240-1245.	3.3	67
117	Medication Overuse Headache and Applicability of the ICHD-II Diagnostic Criteria: 1-Year Follow-Up Study (CARE I Protocol). Cephalalgia, 2009, 29, 233-243.	3.9	47
118	Proposals for New Standardized General Diagnostic Criteria for the Secondary Headaches. Cephalalgia, 2009, 29, 1331-1336.	3.9	42
119	Eletriptan. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 1587-1598.	3.3	10
120	The role of rehabilitation in deep brain stimulation of the subthalamic nucleus for Parkinson's disease: A pilot study. Parkinsonism and Related Disorders, 2009, 15, 675-681.	2.2	25
121	The interplay of two single nucleotide polymorphisms in the CACNA1A gene may contribute to migraine susceptibility. Neuroscience Letters, 2009, 453, 12-15.	2.1	14
122	Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. Neuroscience Letters, 2009, 467, 203-207.	2.1	75
123	Report of ten years' activity in an Alzheimer's disease assessment unit. Aging Clinical and Experimental Research, 2009, 21, 365-368.	2.9	10
124	Calcium Homeostasis Is Dysregulated in Parkinsonian Patients With I-DOPA-Induced Dyskinesias. Clinical Neuropharmacology, 2009, 32, 133-139.	0.7	20
125	Dysphagia in multiple sclerosis: from pathogenesis to diagnosis. Neurological Sciences, 2008, 29, 360-363.	1.9	46
126	Meeting patient expectations in migraine treatment: what are the key endpoints?. Journal of Headache and Pain, 2008, 9, 207-213.	6.0	12

#	Article	IF	CITATIONS
127	Has time come for a re-assessment of spa therapy? The NAIADE survey in Italy. International Journal of Biometeorology, 2008, 52, 231-237.	3.0	13
128	REM behavior disorder, hallucinations and cognitive impairment in Parkinson's disease: A twoâ€year follow up. Movement Disorders, 2008, 23, 1441-1445.	3.9	85
129	Proteasomal inhibition and apoptosis regulatory changes in human isolated lymphocytes: The synergistic role of dopamine. Journal of Cellular Biochemistry, 2008, 103, 877-885.	2.6	4
130	ICHD-II Diagnostic Criteria for Tolosa—Hunt Syndrome in Idiopathic Inflammatory Syndromes of the Orbit and/or the Cavernous Sinus. Cephalalgia, 2008, 28, 577-584.	3.9	87
131	Reduced Habituation of Trigeminal Reflexes in Patients with Episodic Cluster Headache During Cluster Period. Cephalalgia, 2008, 28, 950-959.	3.9	36
132	The Usefulness and Applicability of a Basic Headache Diary Before First Consultation: Results of a Pilot Study Conducted In Two Centres. Cephalalgia, 2008, 28, 1023-1030.	3.9	32
133	Medication Overuse Headache: Predictors and Rates of Relapse in Migraine Patients With Low Medical Needs. A 1-Year Prospective Study. Cephalalgia, 2008, 28, 1196-1200.	3.9	67
134	Role of central dopaminergic circuitry in pain processing and nitroglycerin-induced hyperalgesia. Brain Research, 2008, 1238, 215-223.	2.2	28
135	5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms. European Journal of Pharmacology, 2008, 580, 43-47.	3.5	19
136	Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiology of Disease, 2008, 29, 161-168.	4.4	96
137	Potential therapeutic usefulness of hydrogen peroxide in conditions of brain ischemia. Medical Hypotheses, 2008, 71, 162.	1.5	0
138	Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson's disease. Experimental Neurology, 2008, 212, 548-551.	4.1	28
139	Use of complementary and alternative medicine by patients with cluster headache: Results of a multi-centre headache clinic survey. Complementary Therapies in Medicine, 2008, 16, 220-227.	2.7	20
140	Antioxidant Effect of Sulphurous Thermal Water on Human Neutrophil Bursts: Chemiluminescence Evaluation. Respiration, 2008, 75, 193-201.	2.6	47
141	Pain as a Nonmotor Symptom of Parkinson Disease. Archives of Neurology, 2008, 65, 1191-4.	4.5	208
142	Duodenal Levodopa Infusion Improves Quality of Life in Advanced Parkinson's Disease. Neurodegenerative Diseases, 2008, 5, 244-246.	1.4	93
143	Chronic daily headache. Expert Review of Neurotherapeutics, 2008, 8, 361-384.	2.8	15
144	Role of calcitonin gene-related peptide and substance P in different models of pain. Cephalalgia, 2008, 28, 114-26.	3.9	58

#	Article	IF	CITATIONS
145	A Role for Brain Cyclooxygenaseâ€2 and Prostaglandinâ€E2 in Migraine: Effects of Nitroglycerin. International Review of Neurobiology, 2007, 82, 373-382.	2.0	36
146	The wolframin His611Arg polymorphism influences medication overuse headache. Neuroscience Letters, 2007, 424, 179-184.	2.1	39
147	Early-onset progressive ataxia associated with the first CACNA1A mutation identified within the l–II loop. Journal of the Neurological Sciences, 2007, 254, 69-71.	0.6	22
148	Homocysteine and Parkinson's disease: A dangerous liaison?. Journal of the Neurological Sciences, 2007, 257, 31-37.	0.6	49
149	Neuroprotective Effect of Nitroglycerin in a Rodent Model of Ischemic Stroke: Evaluation of Bclâ€⊋ Expression. International Review of Neurobiology, 2007, 82, 423-435.	2.0	21
150	Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. European Journal of Neuroscience, 2007, 25, 397-405.	2.6	156
151	Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, mu. International Journal of Clinical Practice, 2007, 61, 1256-1269.	1.7	27
152	Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. Brain Research, 2007, 1176, 53-61.	2.2	34
153	Electrophysiologic patterns of oral-pharyngeal swallowing in parkinsonian syndromes. Neurology, 2007, 68, 583-589.	1.1	85
154	Sleep disorders in Parkinson's disease: facts and new perspectives. Neurological Sciences, 2007, 28, S1-S5.	1.9	15
155	Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology, 2006, 66, 529-534.	1.1	88
156	Peripheral Levels of BDNF and NGF in Primary Headaches. Cephalalgia, 2006, 26, 136-142.	3.9	63
157	Selective lesion of the substantia nigra pars reticulata reduces the cortical Fos expression induced by stimulation of striatal D1-like receptors, in the rat. Experimental Neurology, 2006, 200, 240-244.	4.1	1
158	Cardiovascular dysautonomia as a cause of falls in Parkinson's disease. Parkinsonism and Related Disorders, 2006, 12, 195-204.	2.2	21
159	Uncommon primary headaches. Current Opinion in Neurology, 2006, 19, 299-304.	3.6	15
160	Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches. Menopause, 2006, 13, 818-825.	2.0	29
161	A Novel ATP1A2 Mutation in a Family with FHM Type II. Cephalalgia, 2006, 26, 324-328.	3.9	39
162	Abnormal Modulatory Influence of Diffuse Noxious Inhibitory Controls in Migraine and Chronic Tension-Type Headache Patients. Cephalalgia, 2006, 26, 782-789.	3.9	234

#	Article	IF	CITATIONS
163	Diaries and Calendars for Migraine. A Review. Cephalalgia, 2006, 26, 905-916.	3.9	71
164	New Appendix Criteria Open for a Broader Concept of Chronic Migraine. Cephalalgia, 2006, 26, 742-746.	3.9	846
165	Advice Alone Vs. Structured Detoxification Programmes for Medication Overuse Headache: A Prospective, Randomized, Open-Label Trial in Transformed Migraine Patients With Low Medical Needs. Cephalalgia, 2006, 26, 1097-1105.	3.9	137
166	Bath-Related Headache: The First European Case. Cephalalgia, 2006, 26, 1485-1486.	3.9	10
167	Headache Attributed to Infection: Observations on the IHS Classification (ICHD-II). Cephalalgia, 2006, 26, 1427-1433.	3.9	20
168	Use of Complementary and Alternative Medicine by Patients With Chronic Tension-Type Headache: Results of a Headache Clinic Survey. Headache, 2006, 46, 622-631.	3.9	39
169	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. European Journal of Human Genetics, 2006, 14, 322-331.	2.8	152
170	Prostaglandins, glutamate and nitric oxide synthase mediate nitroglycerin-induced hyperalgesia in the formalin test. European Journal of Pharmacology, 2006, 534, 103-107.	3.5	40
171	Unilateral lesion of the subthalamic nucleus enhances cortical fos expression associated with focally evoked seizures in the rat. Brain Research, 2006, 1101, 145-150.	2.2	7
172	Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiology of Disease, 2006, 22, 1-9.	4.4	92
173	Peripheral inflammation and neuroprotection: Systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease. Neurobiology of Disease, 2006, 24, 492-505.	4.4	43
174	REM sleep behavior disorder, hallucinations, and cognitive impairment in Parkinson's disease. Movement Disorders, 2006, 21, 462-466.	3.9	118
175	Botulinum toxin and neuromotor rehabilitation: An integrated approach to idiopathic cervical dystonia. Movement Disorders, 2006, 21, 2240-2243.	3.9	103
176	Eletriptan: a review and new perspectives. Expert Review of Neurotherapeutics, 2006, 6, 1413-1421.	2.8	7
177	Evaluation of thermal water in patients with functional dyspepsia and irritable bowel syndrome accompanying constipation. World Journal of Gastroenterology, 2006, 12, 2556.	3.3	25
178	Secondary cervical dystonia in iatrogenic hypoparathyroidism associated with extensive brain calcifications. Functional Neurology, 2006, 21, 165-6.	1.3	8
179	Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. Human Reproduction, 2005, 20, 3423-3428.	0.9	35
180	A CARE pathway in medication–overuse headache: the experience of the Headache Centre in Pavia. Journal of Headache and Pain, 2005, 6, 307-309.	6.0	11

#	Article	IF	CITATIONS
181	Single High-Dose Steroid Treatment in Episodic Cluster Headache. Cephalalgia, 2005, 25, 290-295.	3.9	55
182	The International Classification of Headache Disorders, 2nd Edition (ICHD-II)—-Revision of Criteria for 8.2 <i>Medication-Overuse Headache</i> . Cephalalgia, 2005, 25, 460-465.	3.9	417
183	Parthenolide is the Component of Tanacetum Parthenium that Inhibits Nitroglycerin-Induced Fos Activation: Studies in an Animal Model of Migraine. Cephalalgia, 2005, 25, 612-621.	3.9	76
184	Reliability of the Nitroglycerin Provocative Test in the Diagnosis of Neurovascular Headaches. Cephalalgia, 2005, 25, 636-637.	3.9	1
185	Reliability of the Nitroglycerin Provocative Test in the Diagnosis of Neurovascular Headaches: Reply. Cephalalgia, 2005, 25, 637-639.	3.9	1
186	Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine. International Journal of Clinical Practice, 2005, 59, 1356-1365.	1.7	12
187	Comparative analysis of the neuronal activation and cardiovascular effects of nitroglycerin, sodium nitroprusside and l-arginine. Brain Research, 2005, 1051, 17-24.	2.2	20
188	Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in Italy. BMC Health Services Research, 2005, 5, 26.	2.2	20
189	Novel parkin mutations detected in patients with early-onset Parkinson's disease. Movement Disorders, 2005, 20, 424-431.	3.9	60
190	Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Movement Disorders, 2005, 20, 1439-1448.	3.9	219
191	Neurophysiological approach to central pain modulation in primary headaches. Journal of Headache and Pain, 2005, 6, 191-194.	6.0	9
192	Introduction to the new International Classification of Headache Disorders. Journal of Headache and Pain, 2005, 6, 203-204.	6.0	2
193	Patients with headache and functional dyspepsia present meal–induced hypersensitivity of the stomach. Journal of Headache and Pain, 2005, 6, 223-226.	6.0	9
194	www.cefalea.it: the first five years. Journal of Headache and Pain, 2005, 6, 264-267.	6.0	1
195	A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurological Sciences, 2005, 26, 26-31.	1.9	125
196	Familial basilar migraine associated with a new mutation in the ATP1A2 gene. Neurology, 2005, 65, 1826-1828.	1.1	86
197	Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism. Neurology, 2005, 65, 1820-1822.	1.1	46
198	Prevalence, Pattern and Predictors of use of Complementary and Alternative Medicine (CAM) in Migraine Patients Attending a Headache Clinic in Italy. Cephalalgia, 2005, 25, 493-506.	3.9	70

#	Article	IF	CITATIONS
199	Effects of acute and chronic restraint stress on nitroglycerin-induced hyperalgesia in rats. Neuroscience Letters, 2005, 383, 7-11.	2.1	63
200	17β-Estradiol Reduces Neuronal Apoptosis Induced by HIV-1 gp120 in the Neocortex of Rat. NeuroToxicology, 2005, 26, 893-903.	3.0	29
201	Activation of the Transcription Factor NF-κB in the Nucleus Trigeminalis Caudalis in an Animal Model of Migraine. NeuroToxicology, 2005, 26, 795-800.	3.0	49
202	Oxidative stress and pro-apoptotic conditions in a rodent model of Wilson's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1741, 325-330.	3.8	42
203	Clinical and genetic studies in hereditary spastic paraplegia with thin corpus callosum. Neurology, 2004, 62, 262-268.	1.1	82
204	Effects of homocysteine on apoptosis-related proteins and anti-oxidant systems in isolated human lymphocytes. FEBS Journal, 2004, 271, 1671-1676.	0.2	13
205	Enhanced anandamide degradation is associated with neuronal apoptosis induced by the HIV-1 coat glycoprotein gp120 in the rat neocortex. Journal of Neurochemistry, 2004, 89, 1293-1300.	3.9	22
206	Retinal Migraine as Unusual Feature of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). Cephalalgia, 2004, 24, 74-77.	3.9	11
207	Reliability of the Nitroglycerin Provocative Test in the Diagnosis of Neurovascular Headaches. Cephalalgia, 2004, 24, 110-119.	3.9	127
208	Characteristics of Menstrual and Nonmenstrual Attacks in Women with Menstrually Related Migraine Referred to Headache Centres. Cephalalgia, 2004, 24, 707-716.	3.9	188
209	Placebo-Controlled Comparison of Effervescent Acetylsalicylic Acid, Sumatriptan and Ibuprofen in the Treatment of Migraine Attacks. Cephalalgia, 2004, 24, 947-954.	3.9	105
210	Spontaneous Intracranial Hypotension Syndrome: Report of Twelve Cases. Headache, 2004, 44, 615-622.	3.9	98
211	Involvement of a Glutamatergic Mechanism in δ-Dendrotoxin-Induced Hippocampal Neuronal Cell Loss in the Rat. Basic and Clinical Pharmacology and Toxicology, 2004, 94, 132-138.	2.5	6
212	Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptor-dependent protective effect. Free Radical Biology and Medicine, 2004, 36, 1233-1240.	2.9	57
213	Comorbid disorders and hospitalisation in Parkinson?s disease: a prospective study. Neurological Sciences, 2004, 25, 66-71.	1.9	73
214	Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson?s disease. The effect of dopaminergic treatment. Journal of Neural Transmission, 2004, 111, 1017-30.	2.8	58
215	Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Experimental Neurology, 2004, 187, 455-459.	4.1	114
216	Effects of diffuse noxious inhibitory controls on temporal summation of the RIII reflex in humans. Pain, 2004, 112, 353-360.	4.2	118

#	Article	IF	CITATIONS
217	Nitroglycerin enhances cGMP expression in specific neuronal and cerebrovascular structures of the rat brain. Journal of Chemical Neuroanatomy, 2004, 27, 23-32.	2.1	32
218	Inducible nitric oxide synthase is involved in the mechanisms of cocaine enhanced neuronal apoptosis induced by HIV-1 gp120 in theneocortex of rat. Neuroscience Letters, 2004, 356, 183-186.	2.1	37
219	Estradiol reduces cytochrome c translocation and minimizes hippocampal damage caused by transient global ischemia in rat. Neuroscience Letters, 2004, 368, 87-91.	2.1	53
220	Long-Term Evaluation of the Effect of Quetiapine on Hallucinations, Delusions and Motor Function in Advanced Parkinson Disease. Clinical Neuropharmacology, 2004, 27, 33-37.	0.7	27
221	Hypnic headache. Neurology, 2004, 62, 1411-1413.	1.1	63
222	A questionnaire on sleep and mental disorders in Parkinson's disease (QSMDPD): development and application of a new screening tool. Functional Neurology, 2004, 19, 83-99.	1.3	11
223	Dopaminergic Modulation of Apoptosis in Human Peripheral Blood Mononuclear Cells. Annals of the New York Academy of Sciences, 2003, 1010, 679-682.	3.8	22
224	Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson?s disease. Neurological Sciences, 2003, 24, 157-158.	1.9	16
225	Neuroprotective effects mediated by dopamine receptor agonists against malonate-induced lesion in the rat striatum. Neurological Sciences, 2003, 24, 180-181.	1.9	10
226	Sleep attacks in Parkinson?s disease: a clinical and polysomnographic study. Neurological Sciences, 2003, 24, 195-196.	1.9	13
227	Reducing the costs of headache: an Italian approach. Journal of Headache and Pain, 2003, 4, s75-s76.	6.0	0
228	Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson?s disease. Journal of Neural Transmission, 2003, 110, 911-922.	2.8	13
229	Nitroglycerin induces hyperalgesia in rats—a time-course study. European Journal of Pharmacology, 2003, 464, 159-162.	3.5	98
230	Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Movement Disorders, 2003, 18, 685-688.	3.9	198
231	Selective stimulation of striatal dopamine receptors of the D1- or D2-class causes opposite changes of fos expression in the rat cerebral cortex. European Journal of Neuroscience, 2003, 17, 763-770.	2.6	23
232	Course of Migraine During Pregnancy and Postpartum: A Prospective Study. Cephalalgia, 2003, 23, 197-205.	3.9	296
233	Parenteral Indomethacin (The Indotest) in Cluster Headache. Cephalalgia, 2003, 23, 193-196.	3.9	29
234	Nitric Oxide Pathway and Response to Nitroglycerin in Cluster Headache Patients: Plasma Nitrite and Citrulline Levels. Cephalalgia, 2003, 23, 407-413.	3.9	31

#	Article	IF	CITATIONS
235	Sunct Syndrome Successfully Treated with Topiramate: Case Reports. Cephalalgia, 2003, 23, 998-1000.	3.9	65
236	Peripheral and Central Activation of Trigeminal Pain Pathways in Migraine: Data From Experimental Animal Models. Cephalalgia, 2003, 23, 1-4.	3.9	36
237	Dietary and nutritional patterns in an elderly rural population in Northern and Southern Italy: (I). A cluster analysis of food consumption. European Journal of Clinical Nutrition, 2003, 57, 1514-1521.	2.9	47
238	Dietary and nutritional patterns in an elderly rural population in Northern and Southern Italy: (II). Nutritional profiles associated with food behaviours. European Journal of Clinical Nutrition, 2003, 57, 1522-1529.	2.9	19
239	Neurobiological mediators of neuronal apoptosis in experimental neuroAIDS. Toxicology Letters, 2003, 139, 199-206.	0.8	19
240	Tolerability of the Triptans. Drug Safety, 2003, 26, 93-107.	3.2	41
241	Early and long-term outcome of rehabilitation in stroke patients: The role of patient characteristics, time of initiation, and duration of interventions. Archives of Physical Medicine and Rehabilitation, 2003, 84, 551-558.	0.9	154
242	Autosomal dominant external ophthalmoplegia and bipolar affective disorder associated with a mutation in the ANT1 gene. Neuromuscular Disorders, 2003, 13, 162-165.	0.6	95
243	Central Components of the Analgesic/Antihyperalgesic Effect of Nimesulide. Drugs, 2003, 63, 9-22.	10.9	31
244	Migraine-like disorder segregating with mtDNA 14484 Leber hereditary optic neuropathy mutation. Neurology, 2003, 60, 717-719.	1.1	23
245	Title is missing!. Psychiatric Genetics, 2003, 13, 121-126.	1.1	4
246	High-Dose Ropinirole in Advanced Parkinson's Disease With Severe Dyskinesias. Clinical Neuropharmacology, 2003, 26, 146-150.	0.7	37
247	Multicentre Italian family-based association study on tyrosine hydroxylase, catechol-O-methyl transferase and Wolfram syndrome 1 polymorphisms in mood disorders. Psychiatric Genetics, 2003, 13, 121-126.	1.1	26
248	Neuroendocrine Response to the Serotonin Agonist M-Chlorophenylpiperazine in Women with Menstrual Status migrainosus. Neuroendocrinology, 2003, 78, 52-60.	2.5	18
249	Klinische, funktionelle und Änderungen der Lebensqualitäbei Patienten mit Krampfadern nach Thermalbad in schwefelhaltigem Wasser. Vasa - European Journal of Vascular Medicine, 2003, 32, 26-30.	1.4	28
250	Cholinesterase inhibitors in Alzheimer's disease: efficacy in a non-selected population. Functional Neurology, 2003, 18, 233-7.	1.3	9
251	<i>SPG3A</i> . Neurology, 2002, 59, 2002-2005.	1.1	45
252	Hallucinations and sleep-wake cycle in PD. Neurology, 2002, 59, 1979-1981.	1.1	112

#	Article	IF	CITATIONS
253	Reversible Chorea and Focal Dystonia in Vitamin B12Deficiency. New England Journal of Medicine, 2002, 347, 295-295.	27.0	25
254	Expression polymorphism of the blood???brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics and Genomics, 2002, 12, 529-534.	5.7	176
255	Dopamine Receptor Agonists Mediate Neuroprotection in Malonate-Induced Striatal Lesion in the Rat. Experimental Neurology, 2002, 178, 301-305.	4.1	14
256	Electrophysiological evidence for trigeminal neuron sensitization in patients with migraine. Neuroscience Letters, 2002, 317, 135-138.	2.1	77
257	Effects of nimesulide on nitric oxide-induced hyperalgesia in humans—a neurophysiological study. European Journal of Pharmacology, 2002, 450, 259-262.	3.5	29
258	Familyâ€based association study of 5â€HTTLPR, TPH, MAOâ€A, and DRD4 polymorphisms in mood disorders. American Journal of Medical Genetics Part A, 2002, 114, 361-369.	2.4	57
259	Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain. Neurological Sciences, 2002, 23, s57-s58.	1.9	2
260	Parkinson's disease and reproductive life events. Neurological Sciences, 2002, 23, s85-s86.	1.9	11
261	Impaired Circadian Rhythmicity of Nociceptive Reflex Threshold in Cluster Headache. Headache, 2002, 42, 125-131.	3.9	33
262	Hormone Supplementation Differently Affects Migraine in Postmenopausal Women. Headache, 2002, 42, 924-929.	3.9	69
263	Nitroglycerin-Induced Activation of Monoaminergic Transmission in the Rat. Cephalalgia, 2002, 22, 226-232.	3.9	29
264	3D Kinematic Analysis and Clinical Evaluation of Neck Movements in Patients with Whiplash Injury. Cephalalgia, 2002, 22, 533-542.	3.9	39
265	Efficacy and Tolerability in Migraine Prophylaxis of Flunarizine in Reduced Doses: A Comparison with Propranolol 160 Mg Daily. Cephalalgia, 2002, 22, 209-221.	3.9	103
266	Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiology and Drug Safety, 2002, 11, 149-157.	1.9	51
267	Report of eight new cases of hypnic headache and mini-review of the literature. Functional Neurology, 2002, 17, 211-9.	1.3	23
268	Diagnostic issues in chronic daily headache. Current Pain and Headache Reports, 2001, 5, 551-556.	2.9	6
269	Plasma Homocysteine and I-DOPA Metabolism in Patients with Parkinson Disease. Clinical Chemistry, 2001, 47, 1102-1104.	3.2	98
270	Effects of Sleep on Spinal Nociceptive Reflexes in Humans. Sleep, 2001, 24, 13-17.	1.1	48

#	Article	IF	CITATIONS
271	Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions. Neurological Sciences, 2001, 22, 49-50.	1.9	27
272	Neurophysiology of migraine. Journal of Headache and Pain, 2001, 2, s67-s71.	6.0	2
273	The prevalence of dementia and cognitive deficit in a rural population of 2442 residents in northern Italy. A door-to-door survey. European Journal of Neurology, 2001, 8, 595-600.	3.3	22
274	Cervicogenic Headache: Evaluation of the Original Diagnostic Criteria. Cephalalgia, 2001, 21, 573-583.	3.9	106
275	Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Annals of Neurology, 2001, 49, 525-529.	5.3	65
276	Nutrition and cognitive deficit in the elderly: a population study. European Journal of Clinical Nutrition, 2001, 55, 1053-1058.	2.9	70
277	Lamotrigine in the treatment of SUNCT syndrome. Neurology, 2001, 57, 1723-1725.	1.1	120
278	Alpha-dihydroergocryptine and predictive factors in migraine prophylaxis. International Journal of Clinical Pharmacology and Therapeutics, 2001, 39, 144-151.	0.6	7
279	Active Music Therapy in Parkinson's Disease: An Integrative Method for Motor and Emotional Rehabilitation. Psychosomatic Medicine, 2000, 62, 386-393.	2.0	282
280	Assessing the Relative Incidence of Mitochondrial DNA A3243G in Migraine Without Aura With Maternal Inheritance. Headache, 2000, 40, 568-571.	3.9	17
281	The Effect of Intranasal Cocaine and Lidocaine on Nitroglycerinâ€Induced Attacks in Cluster Headache. Cephalalgia, 2000, 20, 85-91.	3.9	123
282	Botulinum toxin treatment for functional disability induced by essential tremor. Neurological Sciences, 2000, 21, 349-353.	1.9	45
283	Guillain-Barrï;½ syndrome: an Italian multicentre case-control study. Neurological Sciences, 2000, 21, 229-234.	1.9	50
284	mtDNA A3243G MELAS mutation is not associated with multigenerational female migraine. Neurology, 2000, 54, 1005-1007.	1.1	18
285	Stimulating Effect of HIV-1 Coat Protein gp120 on Corticotropin-Releasing Hormone and Arginine Vasopressin in the Rat Hypothalamus: Involvement of Nitric Oxide. Experimental Neurology, 2000, 166, 376-384.	4.1	36
286	Functional changes of the basal ganglia circuitry in Parkinson's disease. Progress in Neurobiology, 2000, 62, 63-88.	5.7	477
287	Effects of hypnosis on diffuse noxious inhibitory controls. Physiology and Behavior, 2000, 69, 295-300.	2.1	46
288	Asymmetrical reduction of the nociceptive flexion reflex threshold in cluster headache. Cephalalgia, 2000, 20, 647-652.	3.9	9

#	Article	IF	CITATIONS
289	Migraine with aura and reproductive life events: a case control study. Cephalalgia, 2000, 20, 701-707.	3.9	143
290	Memory Functioning at Menopause: Impact of Age in Ovariectomized Women. Gynecologic and Obstetric Investigation, 1999, 47, 29-36.	1.6	136
291	Determination of hydroxyl free radical formation in human platelets using high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1999, 732, 213-220.	1.7	17
292	Unbalanced Randomization Influences Placebo Response: Scientific Versus Ethical Issues Around the Use of Placebo in Migraine Trials. Cephalalgia, 1999, 19, 699-700.	3.9	86
293	Psychiatric Comorbidity and Psychosocial Stress in Patients with Tension-Type Headache From Headache Centers in Italy. Cephalalgia, 1999, 19, 159-164.	3.9	113
294	Chronic Daily Headache. How Should it Be Included in the IHS Classification?. Headache, 1999, 39, 197-203.	3.9	27
295	Bromocriptine test in the evaluation of patients with syncope of unknown aetiology. Acta Neurologica Scandinavica, 1999, 99, 297-302.	2.1	2
296	Modifications of Local Cerebral Metabolic Rates for Glucose and Motor Behavior in Rats with Unilateral Lesion of the Subthalamic Nucleus. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 149-154.	4.3	5
297	Primary headaches: Diagnosis and treatment. Current Review of Pain, 1999, 3, 100-108.	0.7	1
298	Reciprocal circuits involved in nitroglycerin-induced neuronal activation of autonomic regions and pain pathways: a double immunolabeling and tract-tracing study. Brain Research, 1999, 842, 294-310.	2.2	12
299	Peripheral markers of oxidative stress in Parkinson's disease. the role of L-DOPA. Free Radical Biology and Medicine, 1999, 27, 428-437.	2.9	44
300	An Italian-Australian comparison of quality of life among people with intellectual disability living in the community. Journal of Intellectual Disability Research, 1999, 43, 513-522.	2.0	30
301	Different effect of high doses of naloxone on spinal reflexes in normal subjects and chronic paraplegic patients. Neuroscience Letters, 1999, 261, 5-8.	2.1	20
302	The effects on the central nervous system of nitroglycerin—putative mechanisms and mediators. Progress in Neurobiology, 1999, 57, 607-624.	5.7	81
303	Vasomotor response to CO2 and L-Arginine in patients with severe internal carotid artery stenosis; pre- and post-surgical evaluation with transcranial Doppler. Journal of the Neurological Sciences, 1999, 163, 153-158.	0.6	26
304	Experimental models for the study of cluster headache. Italian Journal of Neurological Sciences, 1999, 20, S21-S24.	0.1	2
305	Neurophysiological approach to the study of cluster headache. Italian Journal of Neurological Sciences, 1999, 20, S31-S33.	0.1	2
306	Importance of bioavailable calcium drinking water for the maintenance of bone mass in post-menopausal women. Journal of Endocrinological Investigation, 1999, 22, 852-856.	3.3	32

#	Article	IF	CITATIONS
307	Hydroxyl radical production in the substantia nigra after 6-hydroxydopamine and hypoxia-reoxygenation. Brain Research, 1998, 813, 18-25.	2.2	19
308	Quantitative study of mitochondrial complex I in platelets of parkinsonian patients. Movement Disorders, 1998, 13, 11-15.	3.9	41
309	Endotoxin stimulates an endogenous pathway regulating corticotropin-releasing hormone and vasopressin release involving the generation of nitric oxide and carbon monoxide. Journal of Neuroimmunology, 1998, 86, 104-109.	2.3	41
310	Cerebral Hemodynamics in Primary Headaches: The Transcranial Doppler Experience. Cephalalgia, 1998, 18, 17-22.	3.9	5
311	Headache as a Major Public Health Problem: Current Status. Cephalalgia, 1998, 18, 66-69.	3.9	26
312	Indomethacin increases the effect of isosorbide dinitrate on cerebral hemodynamic in migraine patients: pathogenetic and therapeutic implications. Cephalalgia, 1998, 18, 622-630.	3.9	28
313	Combined evaluation of pupillary and cardiovascular responses to cold pressor test in cluster headache patients. Cephalalgia, 1998, 18, 668-674.	3.9	11
314	Headache Coding and Diagnostic-Related Groups: A Survey of One Year's Admissions to a Neurological Department. Cephalalgia, 1998, 18, 73-75.	3.9	1
315	Long-Term Outcome of Migraine. Cephalalgia, 1998, 18, 30-33.	3.9	24
316	Premenstrual Syndrome and Anxiety Disorders: A Psychobiological Link. Psychotherapy and Psychosomatics, 1998, 67, 57-60.	8.8	22
317	Gaseous Neurotransmitters in the Hypothalamus. The Roles of Nitric Oxide and Carbon Monoxide in Neuroendocrinology. Hormone and Metabolic Research, 1997, 29, 477-482.	1.5	25
318	Stimulation of corticotrophin-releasing hormone release by the obese (ob) gene product, leptin, from hypothalamic explants. NeuroReport, 1997, 8, 1131-1134.	1.2	119
319	Post-menopausal changes and dementing illness: Ovarian steroids as the causal link?. Aging Clinical and Experimental Research, 1997, 9, 66-67.	2.9	1
320	Pituitary-adrenal responses to dexamethasone and CRH administration in patients with untreated Parkinson's disease. Aging Clinical and Experimental Research, 1997, 9, 69-70.	2.9	0
321	Long-Term Nicergoline Treatment of Mild to Moderate Senile Dementia. Clinical Drug Investigation, 1997, 13, 308-316.	2.2	17
322	Opposite effects of l-arginine and nitroglycerin on cerebral blood velocity: Nitric oxide precursors and cerebral blood velocity. Journal of the Neurological Sciences, 1997, 150, 71-75.	0.6	22
323	Neurochemical mechanisms of nitroglycerin-induced neuronal activation in rat brain: A pharmacological investigation. Neuropharmacology, 1997, 36, 1417-1424.	4.1	45
004	Draface Caphalalaia 1997 17 5 5		

#	Article	IF	CITATIONS
325	Is seborrhea a sign of autonomic impairment in Parkinson's disease?. Journal of Neural Transmission, 1997, 104, 1295-1304.	2.8	48
326	Simultaneous determination of l-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1997, 700, 278-282.	1.7	33
327	Haemodynamic Correlates of Early and Delayed Responses to Sublingual Administration of Isosorbide Dinitrate in Migraine Patients. Cephalalgia, 1997, 17, 183-187.	3.9	22
328	Effects of Terguride on Anterior Pituitary Function in Parkinsonian Patients Treated with L-Dopa: A Double-Blind Study Versus Placebo. Clinical Neuropharmacology, 1996, 19, 72-80.	0.7	15
329	An assessment of hypothalamo-pituitary-adrenal axis functioning in non-depressed, early abstinent alcoholics. Psychoneuroendocrinology, 1996, 21, 263-275.	2.7	108
330	Pain Pressure Threshold in Cluster Headache Patients. Cephalalgia, 1996, 16, 62-66.	3.9	25
331	Posatirelin in the treatment of vascular dementia: a double-blind multicentre study vs placebo. Acta Neurologica Scandinavica, 1996, 93, 456-463.	2.1	20
332	Risposta vasomotoria cerebrale alla stimolazione con CO2 e L-Arginina. The Neuroradiology Journal, 1996, 9, 143-151.	0.1	0
333	Free Communications (Section D). Journal of Neuroimaging, 1995, 5, s88.	2.0	0
334	Sleep-apnoea and autonomic dysfunction: a cardiopressor and pupillometric study. Acta Neurologica Scandinavica, 1995, 91, 382-388.	2.1	13
335	Headache and Quality of Life. Headache, 1995, 35, 29-35.	3.9	58
336	Quantification of Headache Disability: A Diagnostic-Based Approach. Headache, 1995, 35, 131-137.	3.9	9
337	?Off? painful dystonia in Parkinson's disease treated with botulinum toxin. Movement Disorders, 1995, 10, 333-336.	3.9	111
338	Classification of Chronic Daily Headache by International Headache Society Criteria: Limits and New Proposals. Cephalalgia, 1995, 15, 37-43.	3.9	113
339	Increased Cerebral Blood Flow Velocity Induced by Cold Pressor Test in Migraine: A Possible Basis for Pathogenesis?. Cephalalgia, 1995, 15, 494-498.	3.9	16
340	Case-Control Study on the Epidemiology of Cluster Headache I: Etiological Factors and Associated Conditions. Neuroepidemiology, 1995, 14, 123-127.	2.3	30
341	Pupillary and cardiovascular responses to the cold-pressor test. Journal of the Autonomic Nervous System, 1995, 55, 45-49.	1.9	48
342	Comparison of teniloxazine and piracetam in alzheimer-type or vascular dementia. Current Therapeutic Research, 1995, 56, 250-257.	1.2	6

#	Article	IF	CITATIONS
343	Combined response of plasma and platelet catecholamines to different types of short-term stress. Life Sciences, 1995, 56, 1113-1120.	4.3	22
344	International Headache Society Classification: Interobserver Reliability in the Diagnosis of Primary Headaches. Cephalalgia, 1994, 14, 16-20.	3.9	64
345	Oral Sumatriptan: Effect of a Second Dose, and Incidence and Treatment of Headache Recurrences. Cephalalgia, 1994, 14, 330-338.	3.9	109
346	Bilateral Asymmetry of Cerebral Blood Velocity in Cluster Headache. Cephalalgia, 1994, 14, 346-351.	3.9	8
347	Comparative Study with EMG, Pressure Algometry and Manual Palpation in Tension-Type Headache and Migraine. Cephalalgia, 1994, 14, 451-457.	3.9	78
348	The neuroendocrine effects of sumatriptan, a specific ligand for 5-HT1-like receptors. Clinical Endocrinology, 1994, 40, 211-214.	2.4	10
349	Intracerebral vascular changes induced by cold pressor test: A model of sympathetic activation. Neurological Research, 1994, 16, 163-167.	1.3	48
350	Reaction time responses in parkinsonian and hemiparkinsonian patients. Movement Disorders, 1993, 8, 13-18.	3.9	14
351	Terguride in fluctuating parkinsonian patients: A double-blind study versus placebo. Movement Disorders, 1993, 8, 463-465.	3.9	10
352	The Nociceptive Flexion Reflex as a Tool for Exploring Pain Control Systems in Headache and Other Pain Syndromes. Cephalalgia, 1993, 13, 21-27.	3.9	84
353	The Trigemino-Pupillary Response in Cluster Headache. Cephalalgia, 1993, 13, 338-342.	3.9	9
354	The Association of Menstrual Migraine with the Premenstrual Syndrome. Cephalalgia, 1993, 13, 422-425.	3.9	91
355	Oral sumatriptan compared with placebo in the acute treatment of migraine. Journal of Neurology, 1993, 241, 138-144.	3.6	59
356	Effectiveness of a Piroxicam Fast Dissolving Formulation Sublingually Administered in the Symptomatic Treatment of Migraine Without Aura. Headache, 1993, 33, 296-300.	3.9	16
357	Imbalance of heart rate regulation in cluster headache as based on continuous 24-h recordings. Clinical Autonomic Research, 1993, 3, 291-298.	2.5	24
358	Effects of dothiepin on nociceptive flexion reflex and diffuse noxious inhibitory controls in humans. European Journal of Pharmacology, 1993, 243, 99-102.	3.5	24
359	The influence of gender in the evaluation of platelet and plasma catecholamines. Life Sciences, 1993, 52, 1995-2004.	4.3	16
360	Sumatriptan in the treatment of migraine attacks. Current Therapeutic Research, 1993, 53, 599-602.	1.2	1

#	Article	IF	CITATIONS
361	Changes in motoneuron excitability of masseter muscle following exteroceptive stimuli in Parkinson's disease. Electroencephalography and Clinical Neurophysiology - Evoked Potentials, 1993, 89, 29-34.	2.0	10
362	Autonomic failure in the degenerative processes of the central nervous system: a critical reappraisal. Journal of the Autonomic Nervous System, 1993, 43, 39-40.	1.9	0
363	Neuroendocrine changes in luteal function in patients with premenstrual syndrome Journal of Clinical Endocrinology and Metabolism, 1993, 76, 1123-1127.	3.6	25
364	An epidemiological approach to the nosography of chronic daily headache. Cephalalgia, 1993, 13, 72-77.	3.9	66
365	Effects of Etoperidone on Sympathetic and Pituitary-Adrenal Responses to Diverse Stressors in Humans. Clinical Neuropharmacology, 1993, 16, 127-138.	0.7	10
366	Carotid Plaques and Multiple Brain Infarctions. Journal of Neuroimaging, 1993, 3, 220-224.	2.0	0
367	Memory impairment in Cushing's disease. Acta Neurologica Scandinavica, 1993, 87, 52-55.	2.1	133
368	Crenokinesitherapy in lower limbs injuries. Pharmacological Research, 1992, 26, 303.	7.1	0
369	Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly. Archives of Gerontology and Geriatrics, 1992, 15, 261-269.	3.0	14
370	The trigemino-pupillary reflex: a model of sensory-vegetative integration. Journal of the Autonomic Nervous System, 1992, 41, 179-185.	1.9	10
371	The brain as a target for adrenocortical steroids: Cognitive implications. Psychoneuroendocrinology, 1992, 17, 343-354.	2.7	124
372	Free plasma catecholamine levels in healthy subjects: A basal and dynamic study. The influence of age. Scandinavian Journal of Clinical and Laboratory Investigation, 1992, 52, 9-17.	1.2	35
373	Evidence of alpha-N-acetyl β-endorphin in human cerebrospinal fluid. Brain Research, 1992, 586, 1-5.	2.2	19
374	Plasma beta-endorphin, cortisol and norepinephrine responses to physical and metabolic stressors in young and elderly humans. Stress and Health, 1992, 8, 1-9.	0.5	0
375	Accompanying Symptoms of Cluster Attacks: Their Relevance to the Diagnostic Criteria. Cephalalgia, 1992, 12, 165-168.	3.9	75
376	A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of 1-dopa, 1-deprenyl and dopaminoagonists. Study design and short term results. Italian Journal of Neurological Sciences, 1992, 13, 735-739.	0.1	11
377	Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1992, 4, 191-205.	1.2	56
378	Impairment of corneal pain perception in cluster headache. Pain, 1991, 47, 299-304.	4.2	46

#	Article	IF	CITATIONS
379	Lornoxicam, A New Non-Steroidal Anti-Iflammatory Drug, in Migraine Prophylaxis: A Double-Blind Multicenter Study. Cephalalgia, 1991, 11, 154-155.	3.9	5
380	Dihydroergokryptine Vs Flunarizine in the Basic Treatment of Migraine without Aura. Cephalalgia, 1991, 11, 216-217.	3.9	3
381	Perimenstrual Headache Prophylaxis with Dihydroergokriptine. Cephalalgia, 1991, 11, 199-200.	3.9	0
382	Plasma Glutathione Level in Chronic Headache Drug Abuser Patients. Cephalalgia, 1991, 11, 186-187.	3.9	0
383	Evidence for the Impairment of Sensory/Nociceptive Integrative Processes in Cluster Headache. The Trigeminal Reflex. Cephalalgia, 1991, 11, 242-243.	3.9	2
384	Antalgic and Antidepressant Activities of Fluoxetine in Daily Chronic Headache. Cephalalgia, 1991, 11, 280-281.	3.9	6
385	Dihydroergocryptine in the Treatment of Parkinson's Disease. Clinical Neuropharmacology, 1991, 14, 78-83.	0.7	14
386	Cardiopressor Effects of Short-term Treatment With Cabergoline in L-Dopa Stable Responder Parkinsonian Patients. Clinical Neuropharmacology, 1991, 14, 343-351.	0.7	5
387	Haemodynamic and neurohormonal responsiveness to different stress tests in mitral valve prolapse. Clinical Autonomic Research, 1991, 1, 323-327.	2.5	4
388	Disordered pupil reactivity in Parkinson's disease. Clinical Autonomic Research, 1991, 1, 55-58.	2.5	76
389	Magnesium Prophylaxis of Menstrual Migraine: Effects on Intracellular Magnesium. Headache, 1991, 31, 298-301.	3.9	218
390	Lisuride plus selegiline in the treatment of early Parkinson's disease. Acta Neurologica Scandinavica, 1991, 83, 407-410.	2.1	21
391	Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1991, 3, 15-25.	1.2	38
392	Neurophysiological Markers of Central and Peripheral Involvement of the Nervous System in HIV-Infection. Clinical EEG (electroencephalography), 1991, 22, 193-198.	0.9	15
393	Personality traits in secondary amenorrhea. Journal of Psychosomatic Obstetrics and Gynaecology, 1991, 12, 67-76.	2.1	6
394	Double Blind Comparison of Lithium and Verapamil in Cluster Headache Prophylaxis. Headache, 1990, 30, 411-417.	3.9	228
395	A New 5-HT2 Antagonist (Ritanserin) in the Treatment of Chronic Headache With Depression. A Double-Blind Study vs Amitriptyline. Headache, 1990, 30, 439-444.	3.9	34
396	Naproxen Sodium in Menstrual Migraine Prophylaxis: A Double-Blind Placebo Controlled Study. Headache, 1990, 30, 705-709.	3.9	145

#	Article	IF	CITATIONS
397	Cerebrospinal fluid corticotropin-releasing factor levels and stimulation test in dementia of the alzheimer type. Journal of Clinical Laboratory Analysis, 1990, 4, 5-8.	2.1	12
398	Effectiveness of Madopar HBS plus Madopar Standard in Patients with Fluctuating Parkinson's Disease: Two Years of Follow-Up. European Neurology, 1990, 30, 319-323.	1.4	16
399	Piroxicam-Î <sup>2</sup> -Cyclodextrin in the Treatment of Headache. Drug Investigation, 1990, 2, 79-85.	0.6	2
400	Neurotensin-induced miosis: The role of dopaminergic pathways. Peptides, 1990, 11, 1309-1311.	2.4	1
401	Dementia of the Alzheimer type and hypothalamus-pituitary-adrenocortical axis: changes in cerebrospinal fluid corticotropin releasing factor and plasma cortisol levels. Acta Neurologica Scandinavica, 1990, 81, 452-456.	2.1	72
402	Effectiveness of Ritanserin, A Selective Serotonin-S2 Receptor Antagonist in the Treatment of Chronic Headache with Dysthymic Disorder. Cephalalgia, 1989, 9, 371-372.	3.9	0
403	Lisuride in Menstrual Migraine Prophylaxis. Cephalalgia, 1989, 9, 444-445.	3.9	7
404	Chronic Paroxysmal Hemicrania: A Chronobiological Study (Case Report). Cephalalgia, 1989, 9, 281-286.	3.9	13
405	Long-Term Efficacy and Safety of Flunarizine in the Prophylaxis of Migraine without Aura. Cephalalgia, 1989, 9, 426-427.	3.9	4
406	Neuroendocrine evidence of deranged noradrenergic activity in chronic migraine. Psychoneuroendocrinology, 1989, 14, 357-363.	2.7	15
407	Electroencephalography in the Early Diagnosis of HIV-Related Subacute Encephalitis: Analysis of 185 Patients. Clinical EEG (electroencephalography), 1989, 20, 1-5.	0.9	37
408	Premenstrual failure of alpha-adrenergic stimulation on hypothalamus-pituitary responses in menstrual migraine Psychosomatic Medicine, 1989, 51, 550-558.	2.0	20
409	A Study of the Cardiopressor Effects of Lisuride in the Treatment of Parkinsonism and Pathological Aging Brain. Clinical Neuropharmacology, 1989, 12, 404-415.	0.7	3
410	Usefulness of computerized electroencephalography in diagnosing, staging and monitoring AIDS-dementia complex. Aids, 1989, 3, 209-214.	2.2	38
411	Naproxen Sodium in the Treatment of Premenstrual Symptoms. Gynecologic and Obstetric Investigation, 1989, 28, 205-208.	1.6	31
412	Weather Interference on Cluster Headache Temporal Pattern. A Cooperative International Long-Term Study. Cephalalgia, 1989, 9, 195-196.	3.9	123
413	Personality Pattern and Analgesic Abuse in Chronic Headache Patients. Cephalalgia, 1989, 9, 246-247.	3.9	1
414	Dihydroergokryptine (DEK) versus Flunarizine (FLU) in Common Migraine. A Multicentre Double-Blind Study. Cephalalgia, 1989, 9, 373-375.	3.9	0

#	Article	IF	CITATIONS
415	N-terminal ACTH fragments increase the CSF β-EP content in Alzheimer type dementia. Acta Neurologica Scandinavica, 1988, 78, 146-151.	2.1	8
416	Effectiveness of Salmon Calcitonin Nasal Spray Preparation in Migraine Treatment. Headache, 1988, 28, 196-200.	3.9	32
417	Cluster Headache in Women: Clinical Findings and Relationship with Reproductive Life. Cephalalgia, 1988, 8, 37-44.	3.9	53
418	Pupil Responsiveness in Cluster Headache: A Dynamic TV Pupillometric Evaluation. Cephalalgia, 1988, 8, 193-201.	3.9	25
419	Neuroendocrine evaluation of central opiate activity in primary headache disorders. Pain, 1988, 34, 29-33.	4.2	18
420	Acetyl-L-Carnitine Acutely Administered Raises β-Endorphin and Cortisol Plasma Levels in Humans. Clinical Neuropharmacology, 1988, 11, 472-477.	0.7	6
421	Aging Brain and Dementias: Changes in Central Opioids. European Neurology, 1988, 28, 217-220.	1.4	18
422	Ritanserin, a Serotonin-S <sub>2</sub> Receptor Antagonist, Does Not Prevent 5-Hydroxytryptophan-Induced β-EP, β-LPH and Cortisol Secretion. Hormone Research, 1987, 27, 42-46.	1.8	12
423	Review: Significance of hormonal changes in migraine and cluster headache. Gynecological Endocrinology, 1987, 1, 295-319.	1.7	21
424	Premenstrual fall of plasma β-endorphin in patients with premenstrual syndrome. Fertility and Sterility, 1987, 47, 570-573.	1.0	54
425	Disordered Pulsatile Lh Release In Cluster Headache. Cephalalgia, 1987, 7, 79-81.	3.9	9
426	Naloxone Test In Primary Headache Sufferers. Cephalalgia, 1987, 7, 39-42.	3.9	3
427	Sympathergic/Neuroendocrine Reactivity As A Marker Of Adaptive Processes Underlying Migraine Susceptibility. Cephalalgia, 1987, 7, 533-535.	3.9	1
428	Involvement Of Serotonin In The Central Control Of Opioid Secretion. Cephalalgia, 1987, 7, 506-513.	3.9	3
429	No gradient exists between lumbar and ventricular cerebrospinal fluid Î <sup>2</sup> -endorphin. Neuroscience Letters, 1987, 77, 349-352.	2.1	13
430	Comparative Efficacy of Cyclandelate versus Flunarizine in the Prophylactic Treatment of Migraine. Drugs, 1987, 33, 103-109.	10.9	17
431	Postprandial and orthostatic hypotension in Parkinson's disease. Neurology, 1987, 37, 386-386.	1.1	92
432	Electroretinographic and visual evoked potential abnormalities in myotonic dystrophy. Electroencephalography and Clinical Neurophysiology, 1986, 64, 215-217.	0.3	21

#	Article	IF	CITATIONS
433	Evidence for serotonin-S2 receptor involvement in analgesia in humans. European Journal of Pharmacology, 1986, 130, 311-314.	3.5	34
434	Dissociation between CSF and plasma B-endorphin in major depressive disorders: evidence for a different regulation. Journal of Endocrinological Investigation, 1986, 9, 11-14.	3.3	12
435	USELESS DRUGS?. Lancet, The, 1986, 328, 1217-1218.	13.7	1
436	Circadian variations of human flexion reflex. Pain, 1986, 25, 403-410.	4.2	61
437	Abnormal dexamethasone suppression test in daily chronic headache sufferers. Psychiatry Research, 1986, 19, 51-57.	3.3	10
438	Dermorphin inhibits spinal nociceptive flexion reflex in humans. Brain Research, 1986, 371, 364-367.	2.2	30
439	Reduced Testosterone Levels in Cluster Headache: A Stress-Related Phenomenon?. Cephalalgia, 1986, 6, 29-34.	3.9	40
440	Effects of L-5HTP With and Without Carbidopa on Plasma β-Endorphin and Pain Perception: Possible Implications in Migraine Prophylaxis. Cephalalgia, 1986, 6, 175-179.	3.9	9
441	Effects of L-5HTP with and Without Carbidopa on Plasma ß-Endorphin and Pain Perception: Possible Implications in Migraine Prophylaxis. Cephalalgia, 1986, 6, 241-245.	3.9	7
442	Dysregulation of plasma pro-opiomelanocortin-related peptides in neurotic depression. European Journal of Endocrinology, 1986, 112, 1-6.	3.7	13
443	CSF and plasma levels of pro-opiomelanocortin-related peptides in reversible ischaemic attacks and strokes Journal of Neurology, Neurosurgery and Psychiatry, 1986, 49, 17-21.	1.9	19
444	Flunarizine in Common Migraine: Italian Cooperative Trial. II. Long-Term Follow-Up. Cephalalgia, 1985, 5, 155-158.	3.9	33
445	CSF Î <sup>2</sup> -EP in Headache and Depression. Cephalalgia, 1985, 5, 99-101.	3.9	23
446	Plasma and CSF Endorphin Levels in Primary and Symptomatic Headaches. Headache, 1985, 25, 141-144.	3.9	21
447	Effects of Lisuride on Blink Reflex Habituation in Parkinson Disease. European Neurology, 1985, 24, 374-379.	1.4	11
448	Endorphin Patterns within the Headache Spectrum Disorders. Cephalalgia, 1985, 5, 201-210.	3.9	27
449	Impairment of adrenergic-induced proopiomelanocortin-related peptide release in heroin addicts. European Journal of Endocrinology, 1985, 108, 1-5.	3.7	18
450	βâ€Endorphin cerebrospinal fluid decrease in untreated parkinsonian patients. Neurology, 1985, 35, 1371-1371.	1.1	55

#	Article	IF	CITATIONS
451	Serotoninergic Agonists Increase Plasma Levels of β-Endorphin and β-Lipotropin in Humans*. Journal of Clinical Endocrinology and Metabolism, 1984, 59, 1138-1142.	3.6	61
452	L-5HTP Treatment in Primary Headaches: An Attempt at Clinical Identification of Responsive Patients. Cephalalgia, 1984, 4, 159-165.	3.9	19
453	Central acth deficit in degenerative and vascular demetria. Life Sciences, 1984, 35, 1691-1697.	4.3	47
454	Concomitant increase in nociceptive flexion reflex threshold and plasma opioids following transcutaneous nerve stimulation. Pain, 1984, 19, 295-303.	4.2	62
455	Progressive impairment of CSF Î <sup>2</sup> -EP levels in migraine sufferers. Pain, 1984, 18, 127-133.	4.2	80
456	Cluster Headache — Clinical Findings in 180 Patients. Cephalalgia, 1983, 3, 21-30.	3.9	249
457	Lithium Carbonate in Cluster Headache: Assessment of Its Short- and Long-Term Therapeutic Efficacy. Cephalalgia, 1983, 3, 109-114.	3.9	67
458	OESTRADIOL/PROGESTERONE IMBALANCE AND THE PREMENSTRUAL SYNDROME. Lancet, The, 1983, 322, 1302.	13.7	19
459	Different patterns of central and peripheral βEP, βLPH and ACTH throughout life. Peptides, 1983, 4, 469-474.	2.4	58
460	Headache Temporal Patterns: Towards a Chronobiological Model. Cephalalgia, 1983, 3, 21-30.	3.9	234
461	Changes of biological rhythms in primary headache syndromes. Cephalalgia, 1983, 3, 58-68.	3.9	30
462	Beta-Endorphin, Beta-Lipotropin and Adrenocorticotropic Hormone Levels in Cerebrospinal Fluid, and Brain Damage in Chronic Alcoholics. European Neurology, 1983, 22, 265-271.	1.4	21
463	Neuroendocrinological signs of central neurotransmission disorders. Cephalalgia, 1983, 3, 122-128.	3.9	1
464	Lithium salts in cluster headache treatment. Cephalalgia, 1983, 3, 79-84.	3.9	8
465	Evaluation of central opioid tonus in menstrual migraine. Cephalalgia, 1983, 3, 98-100.	3.9	2
466	Central Deficiency of β-Endorphin in Alcohol Addicts*. Journal of Clinical Endocrinology and Metabolism, 1982, 55, 583-586.	3.6	166
467	Insulin receptors in myotonic dystrophy: A study with mononuclear leucocytes and erythrocytes. Italian Journal of Neurological Sciences, 1982, 3, 99-106.	0.1	5
468	Membrane processes in myotonic dystrophy duringin vitroaging of erythrocytes. Acta Neurologica Scandinavica, 1982, 65, 661-667.	2.1	0

#	Article	IF	CITATIONS
469	Neuroendocrine Data in Chronic Post-traumatic Headache. Headache, 1982, 22, 38-45.	3.9	5
470	Plasma Opioid Levels in Post-traumatic Chronic Headache and Trigeminal Neuralgia: Maintained Response to Acupuncture. Headache, 1982, 22, 276-279.	3.9	24
471	Changes in the 24-Hour Prolactin Pattern in Cluster Headache. Cephalalgia, 1982, 2, 1-7.	3.9	38
472	Primary Headaches: Reduced Circulating β-Lipotropin and β-Endorphin Levels with Impaired Reactivity to Acupuncture. Cephalalgia, 1981, 1, 195-201.	3.9	88
473	Early splenectomy and polychemotherapy versus polychemotherapy alone in chronic myeloid leukemia. Leukemia Research, 1981, 5, 149-157.	0.8	24
474	Circadian rhythmicity of prolactin secretion in Huntington's Chorea. Life Sciences, 1980, 26, 1609-1617.	4.3	11
475	Reserpine - Headache and PRL Release in Migraine. Headache, 1979, 19, 273-277.	3.9	25
476	Decreased high density lipoprotein-cholesterol levels in male patients with transient ischemic attacks. Atherosclerosis, 1979, 32, 205-211.	0.8	46
477	Hemifacial Spasm Associated with Dolichomegavertebrobasilar Anomaly. European Neurology, 1977, 15, 94-101.	1.4	12
478	Comparative Doppler Directional Sonographic and Ophthalmodynamographic Study in the Occlusion of the Internal Carotid Artery. European Neurology, 1977, 15, 102-108.	1.4	5
479	A Case of Late Onset Lipid Storage Myopathy. European Neurology, 1975, 13, 273-284.	1.4	3
480	Cerebrospinal fluid 5-hydroxyindoleacetic acid level in migrainous patients during spontaneous attacks, during headache-free periods and following treatment withl-tryptophan. Experientia, 1974, 30, 640-641.	1.2	21